Jay O. Knipe

TL;DR: These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations ofHCV inhibitors.

TL;DR: Against tumor cell lines with varying levels of BR96 expression, both conjugates showed potent, antigen-specific cytotoxic activity, suggesting that they will be effective in delivering DOX selectively to antigen-expressing carcinomas.

TL;DR: New N-substituted hydrazine linkers were synthesized and their hydrazone derivatives of adriamycin derivatives were conjugated with a monoclonal antibody and their relationship to the IC50's of the conjugate against 5E9-positive Daudi cells was investigated.

TL;DR: Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in patients chronically infected with HCV genotype 1 when combined with alfa interferon and/or the NS5A replication complex inhibitor daclatasvir as discussed by the authors.

TL;DR: Substrates containing doxorubicin, paclitaxel, and mitomycin C attached to the cathepsin B-sensitive dipeptide Phe-Lys via a self-immolative spacer were prepared as model compounds for internalizing anticancer immunoconjugates.